The Vysis UroVysion(TM) Advantage


  • Detects chromosomal abnormalities associated with the development and progression of bladder cancer.
  • UroVysion in conjunction with cystoscopy delivers the best balance of sensitivity and specificity.1,2
  • UroVysion is not affected by BCG immunotherapy.
  • Detects bladder cancer recurrence up to 6 months sooner than current diagnostic methods.
  • Early detection of high grade disease is critical to increased survival.
References
1 Halling et al., AUA Poster 665, 2001.

2 Halling KC, King W, Sokolova IA, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. Journal of Urology. 2000; 164:1768-1775.

3 UroVysion Package Insert.

4 Bastacky S, Ibrahim S, Wilczynski S, Murphy WM. The accuracy of urinary cytology in daily practice. Cancer Cytopathology. 1999;87:118-128.
The UroVysion Bladder Cancer Kit (UroVysion Kit) is designed to detect aneuploidy for chromosomes 3, 7, 17, and loss of the 9p21 locus via fluorescence in situ hybridization (FISH) in urine specimens from persons with hematuria suspected of having bladder cancer. Results from the UroVysion Kit are intended for use, in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.